Browse by UCL people
Group by: Type | Date
Jump to: Article
Number of items: 12.
Article
Baker, JV;
Hullsiek, KH;
Engen, NW;
Nelson, R;
Chetchotisakd, P;
Gerstoft, J;
Jessen, H;
... INSIGHT START Arterial Elasticity Substudy Team, .; + view all
(2016)
Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) Trial.
Open Forum Infectious Diseases
, 3
(4)
10.1093/ofid/ofw213.
|
 |
|
Bucciardini, R;
Fragola, V;
Massella, M;
Polizzi, C;
Mirra, M;
Goodall, R;
Carey, D;
... Floridia, M; + view all
(2007)
Health related quality of life outcomes in HIV-Infected patients starting different combination regimens in a randomised multinational trial: the INITIO-QoL Substudy.
AIDS Research and Human Retroviruses
, 23
(10)
pp. 1215-1222.
10.1089/aid.2007.0067.
|
|
Davey, RT;
Fernández-Cruz, E;
Markowitz, N;
Pett, S;
Babiker, AG;
Wentworth, D;
Khurana, S;
... INSIGHT FLU-IVIG Study Group; + view all
(2019)
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
The Lancet Respiratory Medicine
, 7
(11)
pp. 951-963.
10.1016/S2213-2600(19)30253-X.
|
|
|
Dickinson, L;
Gurjar, R;
Stöhr, W;
Bonora, S;
Owen, A;
D'Avolio, A;
Cursley, A;
... NEAT001/ANRS143 Study Group, .; + view all
(2020)
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.
Journal of Antimicrobial Chemotherapy
, 75
(3)
pp. 628-639.
10.1093/jac/dkz479.
|
|
Fidler, S;
Stöhr, W;
Pace, M;
Dorrell, L;
Lever, A;
Pett, S;
Kinloch-de Loes, S;
... RIVER trial study group; + view all
(2020)
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
Lancet
, 395
(10227)
pp. 888-898.
10.1016/S0140-6736(19)32990-3.
|
|
Grady, C;
Touloumi, G;
Walker, AS;
Smolskis, M;
Sharma, S;
Babiker, AG;
Pantazis, N;
... START Informed Consent Substudy Group, .; + view all
(2017)
A randomized trial comparing concise and standard consent forms in the START trial.
PLoS ONE
, 12
(4)
, Article e0172607. 10.1371/journal.pone.0172607.
|
|
Holodniy, M;
Brown, ST;
Cameron, DW;
Kyriakides, TC;
Angus, B;
Babiker, A;
Singer, J;
... OPTIMA Team; + view all
(2011)
Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial.
PLOS ONE
, 6
(3)
, Article e14764. 10.1371/journal.pone.0014764.
|
 |
|
Lambert-Niclot, S;
George, EC;
Pozniak, A;
White, E;
Schwimmer, C;
Jessen, H;
Johnson, M;
... NEAT 001/ANRS 143 Study Group, .; + view all
(2016)
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Journal of Antimicrobial Chemotherapy
, 71
(4)
pp. 1056-1062.
10.1093/jac/dkv427.
|
|
Pett, SL;
Kunisaki, KM;
Wentworth, D;
Griffin, TJ;
Kalomenidis, I;
Nahra, R;
Montejano Sanchez, R;
... INSIGHT FLU003 Plus Study Group, .; + view all
(2018)
Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study.
Open Forum Infectious Diseases
, 5
(1)
, Article ofx228. 10.1093/ofid/ofx228.
|
|
|
Schiavone, F;
Bathia, R;
Letchmanan, K;
Masters, L;
Amos, C;
Bara, A;
Brown, L;
... Sydes, MR; + view all
(2019)
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
Trials
, 20
, Article 264. 10.1186/s13063-019-3216-8.
|
|
Thwaites, GE;
Scarborough, M;
Szubert, AJ;
Nsutebu, N;
Tilley, R;
Greig, J;
Wyllie, SA;
... Walker, AS; + view all
(2017)
Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): a multi-centre, randomised, blinded, placebo controlled trial.
The Lancet
10.1016/S0140-6736(17)32456-X.
(In press).
|
|
|
Thwaites, GE;
Scarborough, M;
Szubert, AJ;
Saramango Concalves, P;
Soares, M;
Bostock, J;
Nsutebu, E;
... Walker, AS; + view all
(2018)
Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT.
Health Technology Assessment
, 22
(59)
10.3310/hta22590.
|
|
